Background: Latent transforming growth factor-β-binding protein 1 (LTBP-1) and fibrillin-1 were shown to colocalize and interact in the extracellular matrix of the skin and vasculature. This interaction may regulate transforming growth factor-β (TGF-β) activity. TGF-β is an important progression factor for glomerular diseases. We hypothesized that LTBP-1 and fibrillin-1 are coexpressed in the glomerulus and upregulated during glomerulonephritis. Methods: Acute anti-Thy1.1 glomerulonephritis was induced with a single intravenous injection (1 mg/kg body weight) of a monoclonal anti-Thy1.1 antibody in rats. Real-time RT-PCR and immunohistochemical analyses for LTBP-1 and fibrillin-1 were performed. Results: Induction of glomerular LTBP-1 mRNA was detected on day 2 of disease, while mRNA for fibrillin-1 was already upregulated 1 day after induction of disease. Both LTBP-1 and fibrillin-1 showed a mesangial distribution. An expansion of the LTBP-1 and fibrillin-1-positive mesangial area was seen on day 6 of disease, when transient matrix accumulation was most prominent. On day 12 of disease, glomerular LTBP-1 and fibrillin-1 immunoreactivities had returned to control levels. In serial sections, some colocalization of LTBP-1 and fibrillin-1 was detected in control as well as in nephritic glomeruli. Conclusion: Mesangial expression of LTBP-1 and fibrillin-1 is induced early in experimental nephritis and LTBP-1 and fibrillin-1 are partially colocalized in the nephritic glomerulus. An interaction of these molecules could stabilize latent TGF-β complexes and thus attenuate the activation of TGF-β during this self-limited glomerular disease.

Journal Section:
Original Paper
Keywords:
Glomerulus, Mesangial cells, Extracellular matrix, Microfibrillar proteins, Transforming growth factor-β, Anti-Thy1.1 nephritis
1.
Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J: Latent transforming growth factor-beta binding proteins (LTBPs) – structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999;10:99–117.
[PubMed]
https://doi.org/10.1016%2FS1359-6101%2899%2900010-6
2.
Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF: Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995;131:539–549.
[PubMed]
https://doi.org/10.1083%2Fjcb.131.2.539
3.
Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY: Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003;278:2750–2757.
[PubMed]
https://doi.org/10.1074%2Fjbc.M209256200
4.
Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC: TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114:1586–1592.
[PubMed]
https://doi.org/10.1172%2FJCI200422715
5.
Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC: Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003;33:407–411.
[PubMed]
https://doi.org/10.1038%2Fng1116
6.
Sterzel RB, Hartner A, Schlotzer-Schrehardt U, Voit S, Hausknecht B, Doliana R, Colombatti A, Gibson MA, Braghetta P, Bressan GM: Elastic fiber proteins in the glomerular mesangium in vivo and in cell culture. Kidney Int 2000;58:1588–1602.
[PubMed]
https://doi.org/10.1046%2Fj.1523-1755.2000.00320.x
7.
Hartner A, Hilgers KF, Bitzer M, Veelken R, Schocklmann HO: Dynamic expression patterns of transforming growth factor-beta(2) and transforming growth factor-beta receptors in experimental glomerulonephritis. J Mol Med 2003;81:32–42.
[PubMed]
8.
Minto AW, Wilson HM, Rees AJ, Quigg RJ, Brown PA: Selective expression of TGF-beta2 and TGF-beta3 isoforms in early mesangioproliferative glomerulonephritis. Nephron Exp Nephrol 2004;96:e111–e118.
https://doi.org/10.1159%2F000077377
9.
Hartner A, Cordasic N, Klanke B, Muller U, Sterzel RB, Hilgers KF: The alpha8 integrin chain affords mechanical stability to the glomerular capillary tuft in hypertensive glomerular disease. Am J Pathol 2002;160:861–867.
[PubMed]
10.
Tiedemann K, Batge B, Muller PK, Reinhardt DP: Interactions of fibrillin-1 with heparin/heparan sulfate, implications for microfibrillar assembly. J Biol Chem 2001;276:36035–36042.
[PubMed]
https://doi.org/10.1074%2Fjbc.M104985200
11.
Wada T, Hamakawa S, Hori Y, Kaname S, Shimizu S, Kurokawa K, Katoh T: Immunohistochemical localization of latent transforming growth factor-beta binding protein in IgA nephropathy. Kidney Int Suppl 1997;63:S182–S184.
12.
Hori Y, Katoh T, Hirakata M, Joki N, Kaname S, Fukagawa M, Okuda T, Ohashi H, Fujita T, Miyazono K, Kurokawa K: Anti-latent TGF-beta binding protein-1 antibody or synthetic oligopeptides inhibit extracellular matrix expression induced by stretch in cultured rat mesangial cells. Kidney Int 1998;53:1616–1625.
[PubMed]
https://doi.org/10.1046%2Fj.1523-1755.1998.00908.x
13.
Kielty CM, Wess TJ, Haston L, Ashworth JL, Sherratt MJ, Shuttleworth CA: Fibrillin-rich microfibrils: elastic biopolymers of the extracellular matrix. J Muscle Res Cell Motil 2002;23:581–596.
[PubMed]
https://doi.org/10.1023%2FA%3A1023479010889
14.
Schaefer L, Mihalik D, Babelova A, Krzyzankova M, Grone HJ, Iozzo RV, Young MF, Seidler DG, Lin G, Reinhardt DP, Schaefer RM: Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am J Pathol 2004;165:383–396.
[PubMed]
15.
Sinha S, Heagerty AM, Shuttleworth CA, Kielty CM: Expression of latent TGF-beta binding proteins and association with TGF-beta 1 and fibrillin-1 following arterial injury. Cardiovasc Res 2002;53:971–983.
[PubMed]
https://doi.org/10.1016%2FS0008-6363%2801%2900512-0
16.
Schlotzer-Schrehardt U, Zenkel M, Kuchle M, Sakai LY, Naumann GO: Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 2001;73:765–780.
[PubMed]
https://doi.org/10.1006%2Fexer.2001.1084
17.
Saika S, Miyamoto T, Tanaka T, Ishida I, Ohnishi Y, Ooshima A: Latent TGFbeta binding protein-1 and fibrillin-1 in human capsular opacification and in cultured lens epithelial cells. Br J Ophthalmol 2001;85:1362–1366.
[PubMed]
https://doi.org/10.1136%2Fbjo.85.11.1362
© 2006 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2005
You do not currently have access to this content.